NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
CARMIEL, Israel, May 25, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 7 at 9:00 a.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
A live and archived webcast of the presentation will be available at www.protalix.com, on the event calendar page.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
